Big Pharma More Comfortable Giving Acquired Firms Independence
Big pharma appears increasingly comfortable giving acquired companies operational independence
You may also be interested in...
Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.
Firm looking at 2011-2012 filing for drug candidate, now in Phase III.
AstraZeneca seeks to preserve the entrepreneurial spirit of its acquisitions by giving them the opportunity to operate differently. "Our strategy is ... to bring them into the AstraZeneca family, but make sure they've got the opportunity to operate differently," CEO David Brennan said during AstraZeneca's fourth quarter earnings call Feb. 1